2N Pharma

A small biotech company with a big vision: we want to cure ALS.

[2N Pharma @2NPharma]

@aspcorthals A great article! But then, we’re biased 😀

[2N Pharma @2NPharma]

The RedEye Neurology event is about to start. Hear 2N Pharma’s presentation at 10:40am CET. Joining is free.

https://t.co/q6SH1sNl4J

[2N Pharma @2NPharma]

The 2N team is thrilled to be part of #BioEuropeSpring gathering of innovators in the biotech and life science industry🇪🇸🤩As we dive into the action-packed agenda, we are eager to connect and explore potential collaborations that drive advancements in the field of neuroscience🧠

[2N Pharma @2NPharma]

🌟 Join us at #BIOEuropeSpring today! 🌟
Our team is here and ready to connect and talk about 2N Pharma´s innovative approach for treating #Parkinsons and #ALS.
#BioNeuroscience #drugdevelopment #brainsdiseases #innovation #networking

[2N Pharma @2NPharma]

2N Pharma is on the road. Next week, you can catch us:

In Barcelona for #BIOEuropeSpring
In London for 2nd Ace Drug Discovery Summit (#ADDS) with Dr. John Dirk Vestergaard Nieland as Keynote Speaker. See you there! 🧠
#lifescienceevents #networking #partnerting

[2N Pharma @2NPharma]

Celebrating 4 Years of Innovation at 2N Pharma 💫Over the past four years, we have been dedicated to pioneering breakthroughs in the development of treatments for #ALS and #Parkinsons disease 💊🧠We are immensely grateful to all who have supported us on this journey. Thank you🙏

[2N Pharma @2NPharma]

What a fantastic two days in Amsterdam at the #BioNeuroscience. Not only was the conference amazing, 2N Pharma cleaned up in the pitch competition, winning both Best Pitch and Most Transformational Potential 🎉🏆Thank you to Broadreach Global for organising a fantastic event.

[2N Pharma @2NPharma]

🌟 Join us at the Bio-Neuroscience Summit today! 🌟
Our team, Steinunn Sara Helgudóttir and Preben Bruun-Nyzell, is here and ready to connect and talk about 2N Pharma´s innovative approach for treating
#Parkinsons and #ALS. #BioNeuroscience #innovation

[2N Pharma @2NPharma]

We proudly joined in celebrating the remarkable contributions of #womeninscience. It's inspiring to witness the growing presence of women in #STEM, exemplified by the passion and dedication of our three esteemed female colleagues. #biotech #drugdevelopment

[2N Pharma @2NPharma]

Join us there! https://t.co/8HCCqApIlY

[2N Pharma @2NPharma]

Next week, Preben Bruun-Nyzell (CEO) and Steinunn Helgudóttir (Head of Biology) will attend the Bio-Neuroscience summit in Amsterdam. Along with other professionals in the field of CNS drug development, 2N Pharma is excited to pitch our strategy to developing a treatment for #ALS

[2N Pharma @2NPharma]

Congratulations to 2N Pharma co-founder and CSO, Dr. John Dirk Vestergaard Nieland, for yet another excellent article. This time in BestPractice Nordic DKwhere Dr. Nieland summarises our neurometabolic approach to treating neurodegenerative disorders.
https://t.co/Qt9pcJxxQs

[2N Pharma @2NPharma]

Huge applause as Dr Nieland leaves the stage. Please follow 2N Pharma for more on our work to develop new drugs to treat ALS, Parkinson’s, and other neurodegenerative diseases.

[2N Pharma @2NPharma]

Dr Nieland: Poor dietary choices may be a risk factor. Good choices may help minimise the cellular stress that could contribute to disease development.

[2N Pharma @2NPharma]

Dr. Nieland: The pathway to brain diseases seems to be a combination of genetic predisposition and environmental stress.

[2N Pharma @2NPharma]

Dr Nieland: 2N Pharma’s drug candidate significantly extends survival of mice with ALS. The same is true for Parkinson’s and MS. It is far superior to approved drugs in animal studies.

[2N Pharma @2NPharma]

Dr Nieland: The significance of the Inuit mutation was proven in animal models. Mice with the same mutation are protected from MS (EAE), ALS and Parkinson’s.

[2N Pharma @2NPharma]

Dr Nieland: A prevalent genetic mutation in the Inuit people is strongly correlated with much lower incidence rate of ALS and MS.

[2N Pharma @2NPharma]

Dr Nieland: Deficient glucose metabolism in patients can be seen on FDG-PET scans.

[2N Pharma @2NPharma]

Dr Nieland: Unregulated lipid oxidation is common in ALS, Parkinson’s, Alzheimer’s and may be a key driver of neurodegenerative pathologies.